

Injectable Vaccines for Selected Populations**

Vaccine	Recommendations for use and age	Route	Site ☒	Needle Length*	Contraindications⊕
Meningococcal Conjugate (MCV4)	<ul style="list-style-type: none"> • For children 2-10 yrs who are at high risk for meningococcal disease • Routinely given to adolescents (1 dose) ages 11 through 18 yrs 	IM	Anterolateral Thigh or Deltoid ±	1"-1.5" 22-25 g	Anaphylactic reaction to prior dose or component
Pneumococcal polysaccharide (PPSV 23)	<ul style="list-style-type: none"> • For children 2 yrs and older at high risk for invasive pneumococcal disease • Given after completion of an age-appropriate PCV7 series - Minimum interval of 8 weeks between PCV7 and PPSV23 	IM	Anterolateral Thigh or Deltoid ±	1"-1.5" 22-25 g	Anaphylactic reaction to prior dose or component
		SC	Anterolateral Thigh or Lateral Upper Arm	5/8" 23-25g	

☒ Vaccines should never be administered in the buttocks.

* Professional judgment is appropriate when selecting needle length for use in all children, especially small infants or larger children.

⊕ See package insert for complete contraindication/component listing; components may vary by brand used

» When meningococcal vaccine is indicated and MCV4 is not available, Meningococcal polysaccharide (MPSV4) may be used for persons 2 years and older (given SC). However, if indication is for routine adolescent vaccination (ages 11-18 years), defer until MCV4 is available.

± Use of the deltoid muscle in children 18 months and older (if adequate muscle mass is present) is an option for IM injections.

** Refer to Recommended Childhood and Adolescent Immunization Schedule (available in Child/Adolescent Immunization Section of the AIM Kit) for information on the selected populations.